Covid-19: NPRA approves shelf life extension for Covid-19 Comirnaty vaccine


PUTRAJAYA: The National Pharmaceutical Regulatory Agency (NPRA) has approved a variation application from Pfizer (Malaysia) Sdn Bhd in relation to updating the shelf life of Covid-19 Comirnaty Concentrate for Dispersion for Injection vaccine.

The Health Ministry Pharmacy Services senior director Norhaliza A Halim said the new shelf life is from 15 months to 18 months for vaccine vials stored at -90°C to -60°C.

ALSO READ: Shelf life of seven Covid-19 vaccines extended

She said the extension of the shelf life involved vaccines MAL21016022AZ manufactured by Pfizer Manufacturing Belgium NV and MAL21036039ASZ by BioNTech Manufacturing GmbH, Germany.

"The extension of the product's shelf life has been given based on the latest stability data submitted by the manufacturer.

ALSO READ: Covid-19 vaccine shelf life extended after updated stability data

"The approval of this shelf life extension is retrospective, meaning that this approval also applies to all stocks including all stocks that have been received before this shelf life extension variation is approved,” she said in a statement on Friday (Jan 20).

Norhaliza said the ministry was always committed to ensuring that all pharmaceutical products including the COVID-19 vaccine supplied in Malaysia have been assessed in terms of quality, safety and effectiveness by the NPRA.- Bernama

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

NPRA , MOH , COVID-19 , vaccine , shelf life

   

Next In Nation

Former IGP to be laid to rest at Makam Pahlawan
Citizenship, poverty eradication discussed with Sabah PKR, says Anwar
Aidilfitri Madani 2024 celebration takes centre stage in Sabah
Former IGP Tun Hanif Omar passes away
MULTIMEDIA: FRIM: The Forest That Sprang From Nothing
INTERACTIVE: Get to know Malaysia’s Unesco treasures
Ministries to address parallel pathway issue
This man gets to keep a mistress
Ornamental fish industry gets shot in the arm
KL ranked 22nd for remote work

Others Also Read